NYSE: BIO · Medical Devices
Bio-Rad Laboratories (BIO) fair value: undervalued or overvalued?
As of 31 Oct 2026, Faircurve's model values Bio-Rad Laboratories (BIO) at $350.46 a share. The stock last closed at $369.00, which puts the model's fair value 5.0% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 5 Nov 2026. Bio-Rad Laboratories, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $343.61 to $350.46 (+2.0%). The model shifted weight between the company's own multiple and its peers': most of the move.
What the model makes of itThe price of $369.00 is 5.0% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 11 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give BIO?
The calibrated range for BIO over 63 trading days is $330.77 to $422.06. It sits around the last close, and its width comes from the volatility that BIO's own options imply (37% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $264.93 to $458.03. In 43% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Bio-Rad Laboratories, Inc. was established in 1952 and is headquartered in Hercules, California. It operates as a global provider of life science research and clinical diagnostic products.
Faircurve's model put the fair value at $350.46 a share on 31 Oct 2026, the midpoint of 2,000 simulations. The previous run, on 24 Oct 2026, gave $343.61, so the fair value moved +2.0%. The model says it shifted weight between the company's own multiple and its peers', which is most of the move. The calibrated range over 63 trading days is $334.20 to $444.93, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon, based on 6,661 past valuations. The evidence is graded Medium. The grade does not say whether the fair value is right.
Bio-Rad scores 38 out of 100 on quality against comparable companies, according to the model's composite of six factors. Its balance sheet scores highest at 68, with net debt to EBITDA of 1.33x against a peer median of 3.87x. Stability scores 0, with EBITDA margin downside volatility at 78.0 points over five years against a peer median of 5.8 points. The model compares it with Globus Medical, Align Technology, Bruker, Penumbra, Zimmer Biomet and Haemonetics.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does BIO report earnings, and how has the stock reacted?
Bio-Rad Laboratories's next earnings report is scheduled for 11 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 6.7% in either direction through the nearest expiry, about 14 days out. That is the size the market is pricing, not a direction. BIO's 30 day implied volatility works out to about 10.6% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across BIO's last 8 reports, ignoring direction, was 7.3%.
What the options market has priced for a month's move in BIO
How does BIO score on business quality?
Bio-Rad Laboratories's overall quality score is 38 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 34 | 1.9%ROIC | 3.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 55 | 1.59xFCF / net income | 1.92x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 27 | 0.7%Revenue growth, trailing | 3.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 50 | 1.3%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 68 | 1.33xNet debt / EBITDA | 3.87x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 78.0 ptsEBITDA margin downside volatility, 5y | 5.8 pts |
How does BIO compare with similar companies?
The companies in medical devices closest to Bio-Rad Laboratories in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PODD Insulet Corp. | $156.12 | $193.15 | +23.7% | Low evidence grade |
| GMED Globus Medical, Inc. | $81.44 | $91.57 | +12.4% | Fairly valued |
| ALGN Align Technology, Inc. | $159.37 | $188.05 | +18.0% | Undervalued |
| BRKR Bruker Corporation | $58.06 | $63.61 | +9.6% | Fairly valued |
| PEN Penumbra, Inc. | $321.11 | $291.62 | -9.2% | Fairly valued |
| GKOS Glaukos Corporation | $219.98 | $220.17 | +0.1% | Data under review |
| ZBH Zimmer Biomet Holdings, Inc. | $106.85 | $105.50 | -1.3% | Fairly valued |
| HAE Haemonetics Corporation | $124.11 | $117.17 | -5.6% | Fairly valued |
What the comparable companies' multiples alone would give for BIO, the peer-implied price, is $269.88 a share on this run. The fair value weighs that against the company's own multiple.
Bio-Rad Laboratories at a glance
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products.
- Market value
- $10.0B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $2.7B
- Consensus revenue growth, next fiscal year
- +0.2%
- Analysts with estimates
- 2
- Beta to the US market
- 0.66
- First valued by Faircurve
- 11 Jul 2026
At the close of 5 Nov 2026, 56.0% of the 1,065 graded US stocks the model covers traded below the model's fair value. BIO was not among them.
How the fair value is worked out: the model prices Bio-Rad Laboratories on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for BIO was $343.61. As of 31 Oct 2026 it is $350.46, a change of +2.0%. The model shifted weight between the company's own multiple and its peers': most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Bio-Rad Laboratories's valuation
Is Bio-Rad Laboratories stock undervalued or overvalued?
On Faircurve's model, BIO reads as Fairly valued as of 31 Oct 2026. The model's fair value is $350.46 a share against a last close of $369.00, a gap of -5.0%.
What is BIO's fair value?
$350.46 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $264.93 to $458.03.
What price range does the model give BIO?
$330.77 to $422.06 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Bio-Rad Laboratories report earnings next?
The next report is scheduled for 11 Feb 2027. Companies can move their dates.
How much has BIO moved on past earnings reports?
Across its last 8 reports the median two session move was 7.3%, ignoring direction. The largest was +13.8% around the report of 31 Jul 2025.
How confident is the model in this valuation?
The model's evidence grade for BIO is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on BIO
The model holds no idea open on BIO today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BIO with their outcomes. A free account is enough.